Post Doctoral Scientist-Immuno-Oncology-Fixed Duration Employee

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 39,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We're looking for people who are determined to make life better for people around the world

Responsibilities

We reaffirmed our commitment to invest in R&D facilities across the United States. We're proud to have celebrated the opening of our Immuno-Oncology Research and Development Center of Excellence in New York City. Lilly completed an expansion of our site at the Alexandria Center for Life Science. The site houses a dynamic immuno-oncology R&D center of excellence (IOCE) focused on advancing the next generation of immunotherapies. The research facility represents Lilly's dedication to developing life-changing medicines, and to improving the care of people living with cancer.

With the expansion, we are now looking for a hardworking postdoctoral scientist to join our Immunobiology group. Are you interested in a position that will enable you to work on novel targets as well as established programs? Are you passionate about exploring new aspects of biology? Do you have experience in the field of Immunology? We need someone who is focused, an independent thinker and motivated to design, troubleshoot, perform and document innovative studies.

Your goal as a Postdoctoral scientist would be to provide mechanistic insights and understanding of both a novel checkpoint inhibitor and other IO programs to enable portfolio expansion, as well as early clinical testing and rational combination strategies for advanced clinical trials.

Aim: To explore the development path for novel checkpoint antagonists in cancer.

• MOA in cancer (solid tumors and hematological malignancies)
• Explore role in myeloid biology in the tumor microenvironment
• Identify rationale for combination strategies
• Understand similarities and differences in MOA compared to other checkpoint inhibitors

Aim: To further understand the development path for Lilly portfolio IO agents as immune modulators in cancer

• Explore the relationship between inhibition of the IO pathway with anti-tumor efficacy (e.g. PK/PD relationship, dosing, target engagement)
• Identify combination strategies based on Lilly portfolio
• Identify indications predicted to respond to IO agent as mono- or combination therapy

You will be engaged in exploring potential approaches to programs of humanized models, syngeneic mouse models, gene expression analysis, in vitro assays, 3D-cocultures.

49181BR

Basic Qualifications

• PhD in Immunology, cancer immunology or related discipline

Additional Skills/Preferences

• Immune assay development (human, murine)
• Mouse models of cancer (humanized and syngenic)
• Antigen specific immune assays (OT1, Listeria etc...)
• Peer reviewed publications demonstrating key expertise in immunology (highly desired to be specific to cancer)

Additional Information

• This position is not permanent. It is for a fixed duration of two years with potential to extend annually for up to 4 years.
• Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.